Amgen's new research and development facility in San Francisco. (courtesy photo) A federal appeals court has largely sided with Thousand Oaks-based biotech giant Amgen in a patent infringement suit it brought against two other life sciences firms over its psoriasis drug Otezla. The court on April 19 upheld a permanent injunction issued by a lower…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
